KEGG   DRUG: Acetylsalicylic acid and lansoprazole
Entry
D10527            Mixture   Drug                                   
Name
Acetylsalicylic acid and lansoprazole;
Acetylsalicylic acid and lansoprazole;
Takelda (TN)
Component
Aspirin [DR:D00109], Lansoprazole [DR:D00355]
Class
Metabolizing enzyme substrate
 DG01639  CYP2C19 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 3399
ATC code: B01AC56
Product: D10527<JP>
Efficacy
Antithrombotic
Comment
Lansoprazole is primarily metabolized by CYP2C19 and CYP3A4.
Metabolism
Enzyme: CYP2C19 [HSA:1557], CYP3A4 [HSA:1576]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B01 ANTITHROMBOTIC AGENTS
   B01A ANTITHROMBOTIC AGENTS
    B01AC Platelet aggregation inhibitors excl. heparin
     B01AC56 Acetylsalicylic acid, combinations with proton pump inhibitors
      D10527  Acetylsalicylic acid and lansoprazole <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  33  Blood and body fluid agents
   339  Miscellaneous
    3399  Others
     D10527  Acetylsalicylic acid and lansoprazole
Drug groups [BR:br08330]
 Metabolizing enzyme substrate
  DG01639  CYP2C19 substrate
   D10527  Acetylsalicylic acid and lansoprazole
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10527  Acetylsalicylic acid and lansoprazole
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10527
Other DBs
PubChem: 254741489
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system